



# Mindfulness-based cognitive therapy in COPD: a cluster randomised controlled trial

Ingeborg Farver-Vestergaard<sup>1</sup>, Mia S. O'Toole<sup>1</sup>, Maja O'Connor<sup>1</sup>, Anders Løkke<sup>2</sup>, Elisabeth Bendstrup<sup>2</sup>, Sharee A. Basdeo<sup>3</sup>, Donal J. Cox<sup>3</sup>, Pádraic J. Dunne<sup>3</sup>, Kai Ruggeri<sup>4</sup>, Frances Early<sup>5</sup> and Robert Zachariae<sup>1</sup>

**Affiliations:** <sup>1</sup>Unit for Psychooncology and Health Psychology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark. <sup>2</sup>Dept of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark. <sup>3</sup>Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. <sup>4</sup>Dept of Psychology, University of Cambridge, Cambridge, UK. <sup>5</sup>Centre for Self Management Support, Addenbrooke's Hospital, Cambridge, UK.

**Correspondence:** Ingeborg Farver-Vestergaard, Unit for Psychooncology and Health Psychology, Aarhus University and Aarhus University Hospital, Bartholins Allé 9, 1340, 8000 Aarhus C, Denmark.  
Email: ifarver@psy.au.dk



@ERSpublications

**Mindfulness-based cognitive therapy: an efficacious add-on to PR programmes to reduce psychological distress in COPD** <http://ow.ly/9noC30hnlxr>

**Cite this article as:** Farver-Vestergaard I, O'Toole MS, O'Connor M, *et al.* Mindfulness-based cognitive therapy in COPD: a cluster randomised controlled trial. *Eur Respir J* 2018; 51: 1702082 [<https://doi.org/10.1183/13993003.02082-2017>].

**ABSTRACT** A considerable proportion of patients with chronic obstructive pulmonary disease (COPD) entering pulmonary rehabilitation (PR) report psychological distress, which is often accompanied by poor physical health status. Mindfulness-based cognitive therapy (MBCT) has been shown to improve psychological and physical outcomes in other chronic diseases. We therefore evaluated the efficacy of MBCT as an add-on to a standard PR programme in COPD.

COPD patients eligible for PR were cluster randomised to receive either an 8-week, group-based MBCT programme as an add-on to an 8-week PR programme (n=39), or PR alone (n=45). The primary outcomes of psychological distress and physical health status impairment were measured with the Hospital Anxiety and Depression Scale (HADS) and the COPD Assessment Test (CAT) before randomisation (T1), mid- (T2) and post-intervention (T3), and at 3 (T4) and 6 (T5) months' follow-up.

A statistically significant time×arm effect was found for the HADS (Cohen's  $d=0.62$ , 95% CIs ( $d$ )=0.18–1.06,  $p=0.010$ ). The treatment effect on the CAT failed to reach statistical significance ( $d=0.42$ , 95% CIs ( $d$ )=–0.06–0.90,  $p=0.061$ ).

MBCT showed a statistically significant and durable effect on psychological distress, indicating that MBCT may be an efficacious add-on to standard PR programmes in COPD.

---

Published online Feb 1, 2018; republished Feb 8, 2018 with amendments to table 3.

This article has supplementary material available from [erj.ersjournals.com](http://erj.ersjournals.com)

Received: April 24 2017 | Accepted after revision: Oct 31 2017

**Support statement:** The authors are grateful for the financial support of the independent sources of the Health Research Foundation of Central Denmark Region, The Danish Lung Association Research Foundation, Aase and Ejnar Danielsen's Foundation, and the A. P. Møller and Chastine Mc-Kinney Møller Foundation. Funding information for this article has been deposited with the Crossref Funder Registry.

This trial was pre-registered at [ClinicalTrials.gov](http://ClinicalTrials.gov) (number NCT02042976).

**Conflict of interest:** Disclosures can be found alongside this article at [erj.ersjournals.com](http://erj.ersjournals.com)

Copyright ©ERS 2018

## Introduction

A considerable proportion of patients with chronic obstructive pulmonary disease (COPD) entering pulmonary rehabilitation (PR) report clinically significant levels of psychological distress in the form of anxiety (32%) and depression (27%) [1]. Psychological distress is often undertreated in COPD, and is associated with poor physical outcomes, including physical health status impairment, low physical activity levels and inflammation [2, 3]. The efficacy of psychopharmacological treatment in COPD is limited and patients are often reluctant to take additional medication [4, 5]. Psychosocial intervention has been suggested as an alternative or complementary treatment strategy for reducing psychological distress and physical impairment [3, 6]. This approach is supported by a recent meta-analysis of controlled trials of psychosocial interventions showing reduced psychological distress in COPD, particularly when interventions included cognitive elements [7]. Additionally, another recent meta-analysis [8] indicates that relaxation and meditative techniques have the potential to improve both physical and psychological outcomes in COPD. Taken together, psychosocial interventions that combine cognitive and meditative elements may be effective in improving both psychological and physical outcomes in COPD.

Mindfulness-based cognitive therapy (MBCT) [9] is a group-based intervention that integrates mindfulness meditation with elements of cognitive behavioural therapy. MBCT aims to assist the patient in recognising maladaptive cognitions, emotions and bodily sensations, and relating to them in a non-judgemental and compassionate manner. In contrast to another popular mindfulness-based intervention, mindfulness-based stress reduction, which primarily consists of meditative elements, the combination of cognitive therapy and meditative training in MBCT may be a helpful approach to reduce the self-blaming, catastrophising cognitions and misinterpretations of bodily sensations (e.g. breathlessness) that have been linked to patterns of anxiety, demobilisation and depression in COPD [10, 11]. MBCT has been shown to improve psychological and physical outcomes in other chronic diseases [12], and it could also be effective in COPD. To date, only two studies of relatively limited methodological quality, *i.e.* a small pilot study [13] and a randomised controlled trial with a gender-biased sample [14], have explored the efficacy of mindfulness-based intervention in COPD. The effects found for respiratory rate, emotional function [13], dyspnoea and health-related quality of life [14] did not reach statistical significance or were in the opposite of the expected direction. Both studies used mindfulness-based stress reduction, and no studies so far have explored the efficacy of MBCT in COPD.

The aim of the present study was therefore to test the efficacy of MBCT as an add-on to a standard PR programme in improving the primary outcomes of psychological distress and physical health status impairment in COPD. Our secondary hypotheses were that MBCT would lead to heightened activity levels measured by accelerometers and reduction of the expression of the inflammatory cytokines interleukin (IL)-6, IL-8, tumour necrosis factor alpha (TNF- $\alpha$ ) and IL-17E. These cytokines have previously been shown to be induced by psychological distress [15]; they play a role in COPD pathology [16] and are reduced with mindfulness-based intervention [17]. Additionally, we explored the possible moderating effects of age, gender, MBCT attendance rate and patients' perception of the therapeutic working alliance, together with the potential mediating effects of mindfulness, self-compassion, breathlessness catastrophising and COPD-specific self-efficacy.

## Methods

The study was a cluster randomised controlled trial conducted at Aarhus University Hospital, Denmark, with the intervention arm receiving MBCT as an add-on to a standard PR programme (MBCT+PR) and the active control arm receiving PR only. PR classes were group based and served as units of randomisation. The cluster randomised design was chosen to avoid the risk of contamination bias if individual patients attending the same PR group were randomised to the MBCT+PR and PR-only arms, respectively. As all outcomes were relevant to and reported by individual patients, study objectives pertain to the individual level. Ethics approval was obtained from the Central Denmark Region Committee on Health Research Ethics (number 1-10-72-253-13) and the trial was pre-registered at ClinicalTrials.gov (number NCT02042976).

## Participants

COPD patients referred to PR at Aarhus University Hospital from February 2014 to January 2016 were invited to take part in the study. At the cluster level, all PR groups held at Aarhus University Hospital after the study initiation date were eligible for inclusion. At the individual patient level, inclusion criteria were 1) a spirometry-confirmed (forced expiratory volume in 1 s <50%) COPD diagnosis together with a Medical Research Council dyspnoea score of  $\geq 3$  and 2) physical capability to attend the exercise component of PR. Exclusion criteria were 1) a comorbid diagnosis of stroke, dementia or unstable coronary heart disease and 2) an inability to speak or understand Danish. After receiving written and oral information and providing written consent, patients completed the first questionnaire package. Patients

were then allocated to a PR group (cluster), which was then randomised following the procedure described below.

### **Randomisation and blinding**

PR groups were cluster randomised to either MBCT-PR or PR only. A random allocation sequence of 12 units, corresponding to the planned number of PR groups to be enrolled in the study, was generated by an independent researcher prior to data collection using Power and Sample Size Software (PASS), v.12 (NCSS, Kaysville, UT, USA). Researchers and clinicians involved in patient recruitment were blind to the allocation sequence, which was kept secure. Owing to the nature of psychosocial interventions, patient blinding could not be maintained throughout the intervention, and 2–7 days before the first session of a new PR group, information about the study arm allocation of that particular PR group was provided to patients, research assistants and clinicians.

### **Treatment arms**

The standardised MBCT programme tested in the present study included one 30- to 60-min individual telephone interview followed by eight weekly 105-min group sessions of meditation and educational cognitive exercises. The programme was originally developed to prevent relapse in previously depressed individuals [9]. An adapted treatment manual was developed and piloted with a group of four COPD patients prior to initiation of the present trial (overview in table 1; complete manual in supplementary material). This resulted in four COPD-specific modifications: 1) focus on the heartbeat, the blood flow and the feet's contact with the ground as a means of meditational stabilisation instead of the breath, 2) reduced length and intensity of meditation exercises and home practice, 3) reduced complexity of cognitive exercises and 4) exclusion of the whole-day retreat. The intervention was conducted by a clinical psychologist (I. Farver-Vestergaard). Group sizes varied from three to 13 depending on the number of consenting patients assigned to the respective PR group. Weekly hand-outs and an audio compact disc with meditation exercises were provided to each patient for between-session practice.

The PR programme consisted of two weekly sessions over an 8-week period. One weekly session lasted 90 min, with physical exercise only. The other weekly session lasted 150 min and included physical exercise and disease- and lifestyle-oriented education. The programme followed the guidelines of the American Thoracic Society and the European Respiratory Society [18].

In the MBCT+PR arm, MBCT was added to the PR programme after each of the eight weekly 90-min sessions.

### **Measures**

#### *Primary outcome measures*

Psychological distress was assessed using the Hospital Anxiety and Depression Scale (HADS) [19]. Total scores range from 0 to 42 with higher scores representing higher levels of psychological distress. Internal consistency (Cronbach's  $\alpha$ ) was 0.82 in the present sample [20]. The COPD Assessment Test (CAT) [21] was used to assess physical health status impairment. Total scores range from 0 to 40 with higher scores representing higher levels of physical health status impairment. The measure has shown satisfactory psychometric properties ( $\alpha=0.92$ ) [22]. Data were collected pre- (T1), mid- (4 weeks after first session) (T2) and post intervention (8 weeks after first session) (T3) as well as at 3 (T4) and 6 months (T5) after the final session.

#### *Secondary outcome measures*

Daily physical activity was measured with triaxial accelerometers (ActiGraph Monitor wGT3X-BT) carried around the waist for two periods of 7 days (T1 and T3). The accelerometers stored data at 80 Hz with 10 s epochs (ActiLife Analysis Software, Maribo Medico, Maribo, Denmark). Data were considered valid if the wear time was  $\geq 10$  h per day for  $\geq 4$  days [23]. The average mid-day (10:00–16:00 h) activity level was calculated for each patient at T1 and T3 and expressed as vector magnitude counts per minute (VMcpm, the vectorial sum of activity in the three orthogonal directions measured over a 1-min period) [24]. For analyses of inflammatory cytokines, whole blood samples were collected in 6-mL tubes (PAXgene) at T1 and T3. RT-PCR was carried out as previously described [25], using the following primers: TNF- $\alpha$  (Hs01113624\_g1), IL-6 (Hs01075666\_m1), IL-8 (Hs00174103-m1), IL-17E (Hs03044841\_m1) and 18 s (Hs03003631\_g1).

#### *Moderators*

Age and gender were registered at T1. The number of MBCT sessions attended was registered for each patient in the MBCT+PR arm at T3. Patients' individual perceptions of the therapeutic working alliance

TABLE 1 Overview of the chronic obstructive pulmonary disease-specific mindfulness-based cognitive therapy programme

Session	Theme	Mindfulness exercises	Cognitive exercises	Home work
1	"Awareness and automatic pilot"	"The raisin exercise"; "The body scan"		"The body scan" every day; mindfulness of a routine activity
2	"Living in our heads"	"Awareness of the heartbeat and the blood flow"	"Thoughts and feelings exercise" (noticing connection between thoughts and emotional states); introduction of "the pleasant experiences calendar" (monitoring daily activities and their effects on thoughts, emotions and bodily sensations)	"Awareness of the heartbeat and the blood flow" every day; mindfulness of a routine activity; complete "the pleasant experiences calendar"
3	"Gathering the scattered mind"	"Awareness of the heartbeat, blood flow and body"; "The 3-min breathing space"; "Mindful stretching"	Review of "the pleasant experiences calendar"; introduction of "the unpleasant experiences calendar" (monitoring daily activities and their effects on thoughts, emotions and bodily sensations)	"Mindful stretching" every day; "the 3-min breathing space" 3 pre-scheduled times per day; complete "the unpleasant experiences calendar"
4	"Recognising aversion"	"Awareness of the heartbeat, blood flow, body, sounds and thoughts"; "the 3-min breathing space"	Review of "the unpleasant experiences calendar"; "automatic thoughts exercise" (noticing negative automatic thoughts and their effects on emotions and bodily sensations, and knowing when to do a 3-min breathing space)	"Awareness of the heartbeat, blood flow, body, sounds and thoughts" every day; "the 3-min breathing space" every time something uncomfortable happens
5	"Allowing/letting be"	"Being with the difficult"; "Walking meditation"; "the 3-min breathing space"		"Being with the difficult" every day; "the 3-min breathing space" every time something uncomfortable happens
6	"Thoughts are not facts"	"Awareness of thought and the emotional reaction"; "the 3-min breathing space"	"Mood, thoughts and alternative viewpoints exercise" (our mood can influence how we think about/interpret a situation); "My personal warning system" (noticing personal signals of bad mood and anxiety)	Mindfulness exercise of own choice every day; "the 3-min breathing space" every time something uncomfortable happens"; complete "my personal warning system"
7	"How can I best take care of myself?"	"Awareness of spontaneous reactions of body, emotions, thoughts"; "the 3-min breathing space"	Review of "the personal warning system"; "Activities and mood exercise" (noticing connections between daily activities and mood); introduction of "the action plan" (a personal plan how to best schedule activities when emotions threaten to overwhelm)	Use the mindfulness exercises that you are planning to use after the programme has ended; complete the personal "action plan"
8	"Maintaining and extending new learning"	"The body scan"	Review of "the action plan"	-

The complete manual can be found in the supplementary material.

was assessed with the Working Alliance Inventory (WAI) [26] at T2, and patients were asked to keep a diary of frequency and duration of meditation practice between sessions.

#### Mediators

Mindfulness (Five-Facet Mindfulness Questionnaire (FFMQ) [27]), self-compassion (Self-Compassion Scale (SCS) [28]), breathlessness catastrophising (Breathlessness Catastrophizing Scale (BCS) [29]) and COPD-specific self-efficacy (COPD Self-Efficacy Scale (CSES) [30]) were measured at all time points. FFMQ total scores consisted of four out of five facets [31].

#### Statistical analysis

A *priori* sample size calculations indicated that 2×56 patients would be sufficient to detect an average 3-point reduction in CAT scores after PR with 80% statistical power (two-sided alpha, 5%) [32]. In

addition, the chosen sample size would also allow for detection of a between-group minimal clinically important difference in HADS scores over time of 20% [20] with a statistical power of 78%. Missing items were substituted with the patient's average response on the remaining scale items, if the patient had completed  $\geq 50\%$  of the items [33].

Mixed linear models (MLMs) were chosen to compare MBCT+PR and PR only over time on the primary outcome variables and the secondary outcome variable of activity level, based on the intent-to-treat sample. We specified both two- (time nested within individuals) and three-level models (time nested within individuals nested within clusters). Owing to non-convergence of the models, the final models were specified with only two levels. However, there was no time $\times$ cluster differences over time on primary outcomes (HADS,  $p=0.799$ ; CAT,  $p=0.209$ ). Time was entered as a log-transformation of the time points (*i.e.*, 1–5 [34]). An intervention effect was indicated by a statistically significant two-way interaction between the arm and the time. Treatment moderators were explored as either two-way interaction terms (time $\times$ moderator) in the MBCT+PR arm only – when measures were only available in the MBCT+PR arm (*i.e.*, attendance rate and working alliance) – or three-way interaction terms (time $\times$ arm $\times$ moderator) when measures were available in both arms (*i.e.*, gender and age). Effect sizes were expressed as Cohen's  $d$  derived from the  $F$ -test calculated as  $d=2*\sqrt{(F/df)}$  [35]. All MLMs were estimated with the maximum likelihood method.

In case of a detected effect of MBCT+PR, the FFMQ, the SCS, the BCS and the CSES were explored as mediators in time-lagged analyses [36] where the mediator at time $_x$  predicted the outcome at time $_{x+1}$ , controlling for the outcome variable at time $_x$  and the mediator at time $_{x-1}$ . In case of a significant result, the reverse pattern was also explored in order to test for reciprocal relations. These analyses were conducted on the MBCT+PR group only, where five observation points were available.

Statistical analyses of the fold change in cytokine mRNA expression levels were carried out using Graph Pad software version 6. Two-way ANOVAs were used to compare cytokine mRNA fold change values in the MBCT+PR and PR-only arms from T1 to T3. We also examined correlations between the change in mRNA cytokine expression levels and the change in HADS scores from T1 to T3.

The statistical analyses were conducted with IBM SPSS statistics version 24 and Stata version 14.

## Results

### Participant characteristics

From February 20, 2014, to January 15, 2016, 84 out of 161 patients assessed for eligibility (52%) in 12 clusters consented to participate in the trial (figure 1). 60 patients declined participation (37%) and 17 were ineligible (11%). 14 patients from the intent-to-treat population withdrew from the study, and 12 patients failed to return questionnaires after two unanswered telephone reminders. Eligible patients who declined participation in the study ( $n=60$ ) did not differ statistically significantly from participants in terms of gender, but were statistically significantly older (mean age 71.9 years *versus* 67.2 years,  $p=0.002$ ). Average PR attendance did not differ significantly between the MBCT+PR (mean=10.7 sessions) and PR only (mean=10.0 sessions) arms ( $p=0.434$ ), and was generally similar to the attendance rate reported in an evaluation of the PR service at Aarhus University Hospital, with 55 patients out of 120 completing the programme (unpublished data).

Baseline characteristics are shown in table 2. The treatment arms were well balanced with regard to demographics, clinical characteristics, outcome variables and cluster characteristics, the only exception being use of complementary and alternative medicine over the last year. At baseline, 27.4% of the total sample had clinically significant anxiety levels ( $\geq 10$  points on the HADS anxiety subscale) and 19% had clinically significant depressive symptoms ( $\geq 10$  points on the HADS depression subscale).

### Primary outcomes

Means and standard deviations for the primary outcomes across all time points are shown in table 3 together with the effects. No main effect of time was found for the HADS (Cohen's  $d=0.13$ ,  $p=0.616$ ) or the CAT ( $d=0.16$ ,  $p=0.293$ ). In contrast, a statistically significant time $\times$ arm effect was found for the HADS, corresponding to a medium effect size ( $d=0.62$ ). The effect for the CAT was smaller and did not reach statistical significance. When adjusting the results for multiple comparison with the Benjamini–Hochberg correction, the effect on the HADS remained statistically significant. Two types of sensitivity analyses were then performed for this significant result. First, when analysing the possible association of HADS scores at baseline with subsequent study dropout with logistic regression, no effect was found ( $p=0.932$ ). In addition, when testing the robustness of the observed effect on the HADS with an MLM with the last observation carried forward for study dropouts, the effect remained significant ( $d=0.53$ ,  $p=0.021$ ).




FIGURE 1 Trial profile. MBCT: mindfulness-based cognitive therapy; PR: pulmonary rehabilitation.

Intra-cluster correlation coefficients were 0.02 and 0.21 for the HADS and the CAT, respectively. Supplementary analyses of the HADS depression and anxiety subscales showed a statistically significant time $\times$ arm effect on depression, but not anxiety (table 3).

### Secondary outcomes

A statistically significant increase in TNF- $\alpha$  mRNA from T1 to T3 was found in the PR-only arm, but TNF- $\alpha$  remained unchanged in the MBCT+PR arm (figure 2). The between-arm differences did not reach statistical significance. No statistically significant changes were found in IL-6 and IL-8 mRNA from T1 to T3. IL-17E mRNA was not detectable in the peripheral blood of any patients at any time point analysed and was therefore not subjected to statistical analysis. Correlations between changes in TNF- $\alpha$ , IL-6 and IL-8 mRNA and change in HADS scores were 0.03, 0.05 and 0.008 for MBCT+PR (n=19) and 0.0053, 0.08 and 0.08 for PR only (n=19). Supplementary analyses of the frequency of hospitalisations (p=0.213)

TABLE 2 Baseline characteristics of the intention-to-treat population

	Total (n=84)	Intervention (n=39)	Control (n=45)	p-value <sup>#</sup>
<b>Age years</b>	67.2±7.74	66.67±8.03	67.67±7.54	0.558
<b>Gender</b>				0.449
Women	48 (57.1%)	24 (61.5%)	24 (53.3%)	
Men	36 (42.9%)	15 (38.5%)	21 (46.7%)	
<b>Marital status (n=82)</b>				0.673
Married/cohabiting	40 (48.8%)	19 (51.4%)	21 (46.7%)	
Single/widow(er)	42 (51.2%)	18 (48.6%)	24 (53.3%)	
<b>Educational level (n=81)</b>				0.986
Lower (<2 years of further education)	61 (75.3%)	28 (75.7%)	33 (75.0%)	
Medium (2–4 years of further education)	18 (22.2%)	8 (21.6%)	10 (22.7%)	
Long (≥5 years of further education)	2 (2.5%)	1 (2.7%)	1 (2.3%)	
<b>Occupational status (n=80)</b>				0.928
Full- or part-time work	4 (5.0%)	2 (5.6%)	2 (4.5%)	
Unemployed	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Retired	72 (90.0%)	32 (88.9%)	40 (90.9%)	
Sick leave	4 (5.0%)	2 (5.6%)	2 (4.5%)	
<b>Attitude towards psychotherapy</b>	3.58±1.07	3.55±1.26	3.61±0.92	0.824
<b>Use of psychological support during the last year (n=82)</b>				0.559
Yes	13 (15.9%)	5 (13.5%)	8 (17.8%)	
No	69 (84.1%)	32 (86.5%)	37 (82.2%)	
<b>Use of CAM treatment during the last year (n=79)</b>				0.042
Yes	18 (22.8%)	4 (11.8%)	14 (31.1%)	
No	61 (77.2%)	30 (88.2%)	31 (68.9%)	
<b>Knowledge about mindfulness (n=79)</b>				0.527
Yes	22 (27.8%)	11 (31.4%)	11 (25.0%)	
No	57 (72.2%)	24 (68.6%)	33 (75.0%)	
<b>FEV<sub>1</sub> (% predicted)</b>	37.74±11.76	37.50±12.09	37.94±11.62	0.872
<b>MRC</b>	3.59±0.86	3.56±0.89	3.63±0.84	0.744
<b>BMI</b>	25.75±6.70	25.88±7.25	25.63±6.29	0.893
<b>Comorbidity</b>				
Cancer (n=83)	10 (12.0%)	6 (15.8%)	4 (8.9%)	0.336
Heart condition (n=83)	38 (45.8%)	18 (47.4%)	20 (44.4%)	0.790
Osteoporosis (n=83)	37 (44.6%)	15 (39.5%)	22 (48.9%)	0.390
<b>Smoking (n=81)</b>				0.807
Yes	23 (28.4%)	11 (29.7%)	12 (27.7%)	
No	58 (71.6%)	26 (70.3%)	32 (72.3%)	
<b>Type of treatment</b>				
ICS (n=82)	70 (85.4%)	31 (83.8%)	39 (86.7%)	0.713
LABA (n=82)	77 (93.9%)	35 (94.6%)	42 (93.3%)	0.812
LAMA (n=82)	80 (97.6%)	35 (94.6%)	45 (100.0%)	0.114
PDE4 inhibitors (n=82)	10 (12.2%)	4 (10.8%)	6 (13.3%)	0.728
Home oxygen use (n=81)	4 (4.9%)	2 (5.6%)	2 (4.4%)	0.819
<b>Antidepressant and/or anxiolytic drug treatment during the last year (n=84)</b>	19 (22.6%)	10 (25.6%)	9 (20.0%)	0.538
<b>CAT total (n=71)</b>	19.06±7.08	19.40±7.21	18.80±7.07	0.729
<b>HADS total (n=82)</b>	13.72±7.67	14.04±7.65	13.46±7.77	0.737
<b>Activity level VMcpm (n=62)</b>	389.70 ±166.82	397.11±144.68	382.75±187.29	0.738
<b>IL-6 (n=38)</b>	1.59±1.57	1.54±1.67	1.84±1.53	0.840
<b>IL-8 (n=38)</b>	1.48±1.90	1.10±2.28	1.40±1.48	0.660
<b>TNF-α (n=38)</b>	0.96±0.50	0.84±0.35	1.08±0.60	0.210
<b>Number of PR group (clusters)</b>	12	6	6	
<b>PR group (cluster) size</b>	7.00±2.73	6.50±1.87	7.5±3.51	0.552

Data are presented as mean±SD or n (%). CAM: complementary and alternative medicine; FEV<sub>1</sub>: forced expiratory volume in 1 s; MRC: Medical Research Council dyspnoea score; BMI: body mass index; ICS: inhaled corticosteroids. LABA: long-acting β<sub>2</sub>-agonists; LAMA: long-acting muscarinic antagonists; PDE4: phosphodiesterase 4; CAT: COPD Assessment Test; HADS: Hospital Anxiety and Depression Scale; VMcpm: vector magnitude counts per minute; IL: interleukin; TNF: tumour necrosis factor; PR: pulmonary rehabilitation. #: independent samples t-tests for continuous variables, Chi-squared tests for categorical variables.

TABLE 3 Primary outcomes and effect

	Baseline		Mid-intervention		Post-intervention		3 month follow-up		6 month follow-up	
	MBCT+PR	PR	MBCT+PR	PR	MBCT+PR	PR	MBCT+PR	PR	MBCT+PR	PR
<b>HADS</b>										
Mean±SD	14.04±7.65	13.46±7.77	13.18±7.20	13.71±6.66	12.13±7.08	14.18±8.24	12.08±6.21	15.34±6.95	12.46±5.72	14.74±8.26
N	37	45	30	36	30	37	24	33	25	33
Time × arm interaction: $F=6.9$ , $p=0.010$ ; Cohen's $d=0.62$ ; 95% CI ( $d$ )= 0.18–1.06										
<b>CAT</b>										
Mean±SD	19.40±7.21	18.80±7.07	21.38±5.77	21.09±6.15	18.55±7.19	17.39±4.95	19.25±5.94	21.47±6.21	19.30±6.17	20.55±7.18
N	30	41	31	35	20	18	25	34	25	33
Time × arm interaction: $F=3.6$ ; $p=0.061$ ; Cohen's $d=0.42$ ; 95% CI ( $d$ )= −0.06–0.90										
<b>Supplementary analyses</b>										
<b>HADS-D</b>										
Mean±SD	6.32±3.67	5.90±4.10	5.78±3.57	5.91±3.47	5.33±3.77	6.26±4.60	5.42±3.98	7.17±3.93	5.45±3.03	6.76±4.82
N	37	45	30	36	30	37	24	33	25	33
Time × arm interaction: $F=7.1$ ; $p=0.009$ ; Cohen's $d=0.51$ ; 95% CI ( $d$ )= 0.07–0.95										
<b>HADS-A</b>										
Mean±SD	7.72±4.72	7.57±4.12	7.40±4.22	8.09±4.17	6.80±3.86	7.92±4.16	6.67±2.81	8.17±3.60	7.01±3.44	7.99±4.21
N	37	45	30	37	30	37	24	33	25	33
Time × arm interaction: $F=2.3$ ; $p=0.136$ ; Cohen's $d=0.26$ ; 95% CI ( $d$ )= −0.18–0.70										

MBCT: mindfulness-based cognitive therapy; PR: pulmonary rehabilitation; HADS: Hospital Anxiety and Depression Scale total score; CAT: COPD Assessment Test; HADS-A: HADS anxiety subscore; HADS-D: HADS depression subscore.

and exacerbations ( $p=0.904$ ) indicated no statistically significant time×arm effects at T5. The effect on activity level did not reach statistical significance.

### Moderators

A moderating effect of age was found for the effect on the HADS ( $F=4.3$ ,  $p=0.040$ ;  $d=0.38$ ), indicating a better outcome for younger patients. The moderating effects of gender ( $d=0.31$ ,  $p=0.096$ ), the WAI ( $d=0.83$ ,  $p=0.072$ ) and attendance rate ( $d=0.19$ ,  $p=0.579$ ) did not reach statistical significance. Only three patients in the MBCT+PR arm completed meditation practice diaries, and the data were therefore not subjected to statistical analysis.

### Mediators

Changes in self-compassion (SCS) significantly preceded changes in HADS scores (table 4). The reverse pattern was not significant, ( $B=0.20$ ,  $p=0.227$ ). Changes in the FFMQ, the BCS and the CSES were not significant predictors of subsequent change in the HADS.




FIGURE 2 Tumour necrosis factor (TNF)- $\alpha$  mRNA fold change. \*:  $p<0.05$ .



TABLE 4 Mediators of the effect on Hospital Anxiety and Depression Scale total score

	Baseline		Mid-intervention		Post-intervention		3 month follow-up		6 month follow-up	
	MBCT+PR	PR	MBCT+PR	PR	MBCT+PR	PR	MBCT+PR	PR	MBCT+PR	PR
<b>FFMQ</b>										
Mean±SD	102.51±11.64	104.49±14.68	101.40±14.29	103.52±13.71	107.31±12.84	103.53±12.43	106.77±12.47	102.57±13.46	107.43±14.11	104.65±14.03
N	33	41	30	32	29	35	25	32	24	31
	Time-lagged analysis: B=0.05, p=0.424, 95% CIs (B)= -0.07-0.17									
<b>SCS</b>										
Mean±SD	39.53±5.46	40.22±6.09	39.00±7.26	38.58±5.15	40.36±5.87	39.13±5.15	41.13±6.16	39.00±6.42	39.78±5.92	38.16±5.94
N	34	37	25	33	25	32	24	29	23	31
	Time-lagged analysis: B=0.24, p=0.035, 95% CIs (B)=0.02-0.46									
<b>BCS</b>										
Mean±SD	26.35±13.39	22.04±11.63	22.93±12.36	22.24±10.24	19.34±11.96	21.64±10.25	17.77±10.23	22.91±12.19	18.52±10.69	22.66±13.22
N	37	42	30	34	30	36	25	32	24	32
	Time-lagged analysis: B=0.01, p=0.878, 95% CIs (B)= -0.12-0.14									
<b>CSES</b>										
Mean±SD	90.72±23.94	92.05±22.57	91.10±23.16	93.97±23.30	95.52±27.03	94.53±22.53	95.04±28.16	90.44±22.84	91.32±27.46	91.86±23.24
N	32	41	25	33	27	33	24	32	24	32
	Time-lagged analysis: B=0.03, p=0.337, 95% CIs (B)= -0.03-0.08									

MBCT: mindfulness-based cognitive therapy; PR: pulmonary rehabilitation; FFMQ: Five-Facet Mindfulness Questionnaire, range: 31 (low mindfulness) to 155 (high); SCS: Self Compassion Scale, range: 12 (low self compassion) to 60 (high); BCS: Breathlessness Catastrophizing Scale, range: 0 (low catastrophising) to 52 (high); CSES: COPD Self Efficacy Scale, range: 34 (low self-efficacy) to 170 (high).

## Discussion

Our main findings indicated that MBCT as an add-on to PR led to a clinically relevant reduction (1.5 points [20]) in psychological distress in COPD ( $d=0.62$ ). The effect size was larger than the previously found pooled effect size for psychosocial intervention in COPD (Hedges'  $g=0.38$ ) [7], and was maintained 6 months after termination of the 8-week intervention period. Our results are in disagreement with the earlier studies of mindfulness-based interventions, which found no statistically significant effects on the psychological outcomes of anxiety and perceived stress in COPD [13, 14]. Additional analyses suggested that MBCT relieved psychological distress primarily by reducing symptoms of depression rather than anxiety, which may explain the null findings in earlier studies. Furthermore, the interventions evaluated in earlier studies did not include cognitive elements, and combining elements from mind-body interventions and cognitive behavioural therapy in the MBCT programme for COPD may therefore be more effective than mindfulness meditation only [7]. Our results should be interpreted with caution, as a psychological control component was not added to the PR programme in the control arm (PR only). A statistical trend-wise effect was observed for physical health status impairment ( $d=0.42$ ,  $p=0.061$ ). This effect did not reach a clinically relevant level (a 2.0 point reduction [22]), but was, however, similar to the pooled effect size previously found for effects of mind-body interventions on physical outcomes in COPD ( $g=0.40$ ) [7]. The statistically near-significant effect for this outcome could therefore possibly be explained by the smaller than planned sample size obtained within the time-frame of the present study. There was no effect of time across treatment arms, which was unexpected, as both arms received a standard PR programme previously shown to reduce psychological distress and physical health status impairment [18]. A possible explanation could be that PR prevented a worsening of outcomes, which could otherwise have been the result of the progressive disease of COPD. As PR is part of standard COPD care, it would have been unethical to include a study arm that did not receive PR.

A statistically significant increase in TNF- $\alpha$  from before to after treatment was found in the PR-only control arm, but no changes were observed in MBCT+PR participants. This could indicate that MBCT prevented the exacerbation of TNF- $\alpha$ -mediated inflammation over time. In correspondence with our findings, mindfulness practice has previously been shown to be associated with larger reductions in TNF- $\alpha$  after stress induction in healthy individuals [17]. This specific cytokine is believed to play a role in lung diseases, and inhibiting TNF- $\alpha$  has been proposed as a relevant therapeutic target in inflammatory diseases [37]. Adverse side effects of pharmacological TNF- $\alpha$  inhibitors such as pain and diarrhoea are common in COPD, suggesting the potential relevance of MBCT as an alternative in inflammation control [37]. No effects were found for the remaining inflammatory markers of IL-6, IL-8 and IL-17E. Our use of peripheral blood cells as a biological source of pro-inflammatory cytokine, as opposed to cells from the lung microenvironment, might explain the lack of mRNA expression of these specific cytokines. Examination of tissue resections or bronchoalveolar lavage fluid could perhaps have yielded different results. Our results should therefore be considered preliminary and require further examination in future studies.

No statistically significant effect of the intervention was found for patients' activity levels as measured with accelerometers. In addition to the possibility of insufficient statistical power for this secondary variable, another explanation could be that it takes more than 8 weeks of training for patients to implement the complex behaviour changes needed to observe changes in their average physical activity level [18]. Longer follow-up periods could thus be relevant for activity monitoring in future studies.

Our additional results suggest that age moderates the effect of MBCT on psychological distress, with MBCT appearing to be more effective for younger COPD patients. This is in line with a review stating that younger COPD patients may be more adept at learning the skills and tools taught in psychosocial intervention [38]. This finding may guide clinicians when referring patients to MBCT. The moderating effects of gender, MBCT attendance rate and therapeutic working alliance did not reach statistical significance. The non-significant effect of gender differs from the results reported in the COPD literature of gender differences in medical and behavioural treatment adherence and outcomes [39]. Concerning MBCT attendance, the reasons for non-attendance may vary, including perception of sufficient treatment gain or perceived difficulties in relation to the intervention, which could explain the lack of a moderating effect. We attempted to assess the frequency of home practice, but the number of completed home practice diaries in the present sample was insufficient. Taking the large effect size of therapeutic working alliance into account ( $d=0.83$ ), the non-significant result for this moderator could be due to the relatively limited number of patients in the MBCT+PR arm ( $n=39$ ).

The results of our exploratory mediational analyses suggest that the effect of MBCT on psychological distress may be facilitated through increased levels of self-compassion. Our finding suggests that stimulating a non-judgemental attitude through mindfulness meditation and cognitive exercises may be efficacious in relieving psychological distress in COPD, a disease where feelings of smoking-related self-blame and stigma are highly prevalent and associated with depression [40]. However, other potential mechanisms driving the effect of MBCT in COPD cannot be excluded, and future research should implement more assessment points, *e.g.* at every session, in order to capture more fine-grained dynamics of change.

The present study has several strengths, including a randomised design and a long-term (6 month) follow-up. However, a number of limitations should also be noted. First, as an attention control condition was not added to the PR programme in the PR-only arm, we cannot rule out that additional attention from healthcare professionals may have boosted the effect in the MBCT+PR arm. On the other hand, the validity of our findings is supported by controls receiving an active intervention previously shown to be effective [18]. Second, because of a lower inclusion rate than expected, the final sample size was smaller than projected, which could explain the statistically non-significant effect ( $p=0.061$ ) found for physical health status impairment. The limited enrolment rate could perhaps be due to that not all patients eligible for PR reported clinically significant levels of psychological distress. Third, patients who declined participation in the study were older than participating patients, which could limit the external validity of our results. Fourth, attrition rates were high in both the intervention and the control arm. This is a general issue in COPD research and practice where compliance rates generally are poor [41]. Dropout, however, was balanced across treatment arms and did not appear, as supported by our sensitivity analyses, to compromise the robustness of the results. Finally, the single-site design with only one MBCT instructor and one team of PR providers may limit the generalisability of the results. Taken together, to increase validity of the results, future multi-site trials including larger samples and attention control arms are recommended.

### Acknowledgements

The authors thank all the participating patients, as well as the clinical and administrative staff at the Dept of Respiratory Medicine and Allergy and the Dept of Physiotherapy and Occupational Therapy, Aarhus University Hospital, who made this study possible. Moreover, we wish to thank our colleagues at the Unit for Psychooncology and Health Psychology Maja Johannsen and Eva Rames Nissen for their valuable input and Jesper Dahlgaard (VIA University College, Aarhus) for relevant discussions in relation to analysis of inflammatory markers.

### References

- 1 Janssen DJ, Spruit MA, Leue C, *et al.* Symptoms of anxiety and depression in COPD patients entering pulmonary rehabilitation. *Chron Respir Dis* 2010; 7: 147–157.
- 2 Pumar MI, Gray CR, Walsh JR, *et al.* Anxiety and depression: important psychological comorbidities of COPD. *J Thorac Dis* 2014; 6: 1615–1631.
- 3 Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. *Eur Respir Rev* 2014; 23: 345–349.
- 4 Fritzsche A, Clamor A, von Leupoldt A. Effects of medical and psychological treatment of depression in patients with COPD: a review. *Respir Med* 2011; 105: 1422–1433.

- 5 Yohannes AM, Alexopoulos GS. Pharmacological treatment of depression in older patients with chronic obstructive pulmonary disease: impact on the course of the disease and health outcomes. *Drugs Aging* 2014; 31: 483–492.
- 6 von Leupoldt A, Janssens T. Could targeting disease specific fear and anxiety improve COPD outcomes? *Expert Rev Respir Med* 2016; 10: 835–837.
- 7 Farver-Vestergaard I, Jacobsen D, Zachariae R. Efficacy of psychosocial interventions on psychological and physical health outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Psychother Psychosom* 2015; 84: 37–50.
- 8 Volpato E, Banfi P, Rogers SM, *et al.* Relaxation techniques for people with chronic obstructive pulmonary disease: a systematic review and a meta-analysis. *Evid-Based Complementary Altern Med* 2015: 1–22.
- 9 Segal Z, Williams JMG, Teasdale J. Mindfulness-based cognitive therapy for depression. New York, Guildford Press, 2013.
- 10 Moore MC, Zebb BJ. The catastrophic misinterpretation of physiological distress. *Behav Res Ther* 1999; 37: 1105–1118.
- 11 Livermore N, Sharpe L, McKenzie D. Catastrophic interpretations and anxiety sensitivity as predictors of panic-spectrum psychopathology in chronic obstructive pulmonary disease. *J Psychosom Res* 2012; 72: 388–392.
- 12 Gotink RA, Chu P, Busschbach JJ V, *et al.* Standardised mindfulness-based interventions in healthcare: An overview of systematic reviews and meta-analyses of RCTs. *PLoS One* 2015; 10: 1–17.
- 13 Chan RR, Giardino N, Larson JL. A pilot study: mindfulness meditation intervention in COPD. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 445–454.
- 14 Mularski RA, Munjas BA, Lorenz KA, *et al.* Randomized controlled trial of mindfulness-based therapy for dyspnea in chronic obstructive lung disease. *J Altern Complement Med* 2009; 15: 1083–1090.
- 15 Dowlati Y, Herrmann N, Swardfager W, *et al.* A meta-analysis of cytokines in major depression. *Biol Psychiatry* 2010; 67: 446–457.
- 16 Cazzola M, MacNee W, Martinez FJ, *et al.* Outcomes for COPD pharmacological trials: from lung function to biomarkers. *Eur Respir J* 2008; 31: 416–468.
- 17 Rosenkranz MA, Davidson RJ, Maccoon DG, *et al.* A comparison of mindfulness-based stress reduction and an active control in modulation of neurogenic inflammation. *Brain Behav Immun* 2013; 27: 174–184.
- 18 Spruit MA, Singh SJ, Garvey C, *et al.* An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med* 2013; 188: e13–e64.
- 19 Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* 1983; 67: 361–370.
- 20 Puhan MA, Frey M, Büchi S, *et al.* The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. *Health Qual Life Outcomes* 2008; 6: 46.
- 21 Jones PW, Harding G, Berry P, *et al.* Development and first validation of the COPD Assessment Test. *Eur Respir J* 2009; 34: 648–654.
- 22 Kon SSC, Canavan JL, Jones SE, *et al.* Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. *Lancet Respir Med* 2014; 2: 195–203.
- 23 Friis AL. Dietary beetroot juice – effects on physical performance in COPD patients: a randomized controlled crossover trial. *Int J COPD* 2017; 12: 1765–1773.
- 24 Hecht A, Ma S, Porszasz J, *et al.* Methodology for using long-term accelerometry monitoring to describe daily activity patterns in COPD. *COPD* 2009; 6: 121–129.
- 25 Basdeo SA, Kelly S, O’Connell K, *et al.* Increased expression of Tbet in CD4(+) T cells from clinically isolated syndrome patients at high risk of conversion to clinically definite MS. *Springerplus* 2016; 5: 779.
- 26 Tracey TJ, Kokotovic AM. Factor structure of the Working Alliance Inventory. *Psychol Assess* 1989; 1: 207–210.
- 27 Baer RA, Smith GT, Hopkins J, *et al.* Using self-report assessment methods to explore facets of mindfulness. *Assessment* 2006; 13: 27–45.
- 28 Raes F, Pommier E, Neff KD, *et al.* Construction and factorial validation of a short form of the Self-Compassion Scale. *Clin Psychol Psychother* 2011; 18: 250–255.
- 29 Solomon BK, Wilson KG, Henderson PR, *et al.* A breathlessness catastrophizing scale for chronic obstructive pulmonary disease. *J Psychosom Res* 2015; 79: 62–68.
- 30 Emme C, Mortensen EL, Rydahl-Hansen S, *et al.* Danish version of “The COPD self-efficacy scale”: Translation and psychometric properties. *Scand J Caring Sci* 2012; 26: 615–623.
- 31 Williams MJ, Dalgleish T, Karl A, *et al.* Examining the factor structures of the Five Facet Mindfulness Questionnaire and the Self-Compassion Scale. *Psychol Assess* 2014; 26: 407–418.
- 32 Dodd JW, Hogg L, Nolan J, *et al.* The COPD Assessment Test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. *Thorax* 2011; 66: 425–429.
- 33 Schafer JL, Graham JW. Missing data: our view of the state of the art. *Psychol Methods* 2002; 7: 147–177.
- 34 Tasca GA, Illing V, Joyce AS, *et al.* Three-level multilevel growth models for nested change data: a guide for group treatment researchers. *Psychother Res* 2009; 19: 453–461.
- 35 Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York, Springer-Verlag, 2000.
- 36 Pek J, Hoyle RH. On the (in)validity of tests of simple mediation: threats and solutions. *Soc Personal Psychol Compass* 2016; 10: 150–163.
- 37 Matera MG, Calzetta L, Cazzola M. TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. *Pulm Pharmacol Ther* 2010; 23: 121–128.
- 38 Coventry PA, Gellatly JL. Improving outcomes for COPD patients with mild-to-moderate anxiety and depression: A systematic review of cognitive behavioural therapy. *Br J Health Psychol* 2008; 13: 381–400.
- 39 Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences: an update. *Transl Res* 2013; 162: 208–218.
- 40 Plaufcan MR, Wamboldt FS, Holm KE. Behavioral and characterological self-blame in chronic obstructive pulmonary disease. *J Psychosom Res* 2012; 72: 78–83.
- 41 Blackstock FC, ZuWallack R, Nici L, *et al.* Why don’t our COPD patients listen to us? The enigma of nonadherence. *Ann Am Thorac Soc* 2016; 13: 317–323.